Revista espanola de medicina nuclear e imagen molecular最新文献

{"title":"Vesical displacement due to rectal distension mimicking ureteral obstruction","authors":"H. Elahifard , A. Saber Tanha , M. Ahmadi , M. Saberifar , M.J. Bahonar , R. Sadeghi","doi":"10.1016/j.remnie.2025.500231","DOIUrl":"10.1016/j.remnie.2025.500231","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"45 2","pages":"Article 500231"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145152608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SUMMARY: Selective Sentinel Lymph Node Biopsy (SSLNB) in breast cancer for residents","authors":"R. Caratini ,&nbsp;A. Segarra ,&nbsp;E. Garcia ,&nbsp;K. Quintero ,&nbsp;J. Cordon ,&nbsp;M. Vega ,&nbsp;J. Cases ,&nbsp;I. Cebrecos ,&nbsp;J. Ribera-Perianes ,&nbsp;S. Vidal-Sicart","doi":"10.1016/j.remnie.2025.500261","DOIUrl":"10.1016/j.remnie.2025.500261","url":null,"abstract":"<div><div>This work presents the key aspects of the sentinel lymph node biopsy (SLNB) procedure in breast cancer, based on the protocol used at Hospital Clínic de Barcelona. The aim is to facilitate its generalization in other hospital settings and training environments, promoting the standardization of the technique. It is also intended to serve as a useful resource for resident physicians and other medical trainees.</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"45 2","pages":"Article 500261"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145650268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Portal of entry for Streptococcus gallolyticus in infective endocarditis","authors":"S. de la Torre Fernández,&nbsp;A.K. Minguillan Van Kapel,&nbsp;B. Aradas Cabado,&nbsp;M.J Tello Galán,&nbsp;A.E. Seva Delgado,&nbsp;C.M. Hernández Heredia","doi":"10.1016/j.remnie.2025.500210","DOIUrl":"10.1016/j.remnie.2025.500210","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"45 2","pages":"Article 500210"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144984496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of [18F]FDG PET/CT in follicular lymphoma","authors":"A. Díaz Silván ,&nbsp;D. Cabello García ,&nbsp;L.F. Otón Sánchez","doi":"10.1016/j.remnie.2025.500229","DOIUrl":"10.1016/j.remnie.2025.500229","url":null,"abstract":"<div><h3>Objective</h3><div>To determine the prognostic value of [¹⁸F]FDG PET/CT in follicular lymphoma (FL) patients in our routine clinical practice.</div></div><div><h3>Material and methods</h3><div>Retrospective study of FL patients assessed with PET/CT in our centre from 01/06/2008 to 01/06/2020. This study aimed to investigate the prognostic value of quantitative parameters (MTV, TLG, ΔSUV max) and qualitative criteria (Lugano classification), and its relationships with progression-free survival (PFS) and overall survival (OS).</div></div><div><h3>Results</h3><div>Among patients with available staging PET/CT, the 5-year OS was 90.4% for those with lower MTV and 89.7% for those with higher MTV (p = 0.3). The PFS was 77.6% for those with lower MTV and 53.2% for those with higher MTV (p = 0.001). TLG yielded statistically similar results.</div><div>A ΔSUV max ≥ 66% was associated with higher OS and PFS at 5 years, at both interim and final PET/CT studies (iPET and fPET). The 5-year OS for patients with complete metabolic response was 86.3% in iPET and 89.0% in fPET, compared to 84.1% and 79.0%, respectively, for those positive in iPET (p = 0.3) and fPET (p = 0.1). The 5-year PFS for patients with complete metabolic response was 76.9% in iPET and 73.1% in fPET, compared to 58.7% and 62.2%, respectively, for those positive in iPET (p = 0.04) and fPET (p = 0.09).</div></div><div><h3>Conclusions</h3><div>PET/CT is valuable as a prognostic factor in FL, both during staging (providing parameters with independent prognostic value such as MTV and TLG) and during and after treatment (as it correlates with survival).</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"45 2","pages":"Article 500229"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145067158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multifocal osteonecrosis in pediatric-onset systemic lupus erythematosus","authors":"H. Elahifard ,&nbsp;M.H. Samadi ,&nbsp;E. Askari ,&nbsp;F. Taheri ,&nbsp;S. Abedi ,&nbsp;M. Vahedi","doi":"10.1016/j.remnie.2025.500206","DOIUrl":"10.1016/j.remnie.2025.500206","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"45 2","pages":"Article 500206"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145139958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Selective sentinel lymph node biopsy in breast cancer local recurrence","authors":"L. Rodríguez-Díaz ,&nbsp;P. Zaragoza-Ballester ,&nbsp;I. Torras ,&nbsp;E. Mensión ,&nbsp;I. Cebrecos ,&nbsp;X. Cases ,&nbsp;M. Vega ,&nbsp;J. Cordón ,&nbsp;J. Ribera-Perianes ,&nbsp;S. Vidal-Sicart ,&nbsp;on behalf of the Clínic Barcelona Nuclear Medicine (CBNM) Group","doi":"10.1016/j.remnie.2025.500232","DOIUrl":"10.1016/j.remnie.2025.500232","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>5–10% of breast tumor patients develop local breast tumor recurrence. The absence of axillary re-staging could increase future local recurrence and mortality risk in these patients. The lymphoscintigraphy for sentinel lymph node biopsy in recurrences (rSLNB) using a radiotracer injection, can be an option to evaluate axillar status, but other factors known to alter the usual behaviour of SLN migration have to be taken into account, such as previous axillary surgery, breast surgery or adjuvant treatments. Our objective was to evaluate the relationship between these factors and the success rate of rSLNB (overall and aberrant drainage rates, metastases ratio).</div></div><div><h3>Materials and methods</h3><div>1102 patients were retrospectively evaluated in a tertiary hospital between 10/2018–04/2022. 52 patients with ipsilateral breast tumor recurrence who underwent rSLNB were included. Demographic data, tumor characteristics, previous treatments, drainage rates and characteristics were collected and analyzed (R statistical software).</div></div><div><h3>Results</h3><div>Overall drainage rate was 83%, in which excision was performed in 91%. Overall migration rate was significantly higher in patients with previous SLNB (92% vs 60%, p-value<!--> <!-->=<!--> <!-->0.012) and aberrant drainage was significantly higher in patients with previous axillar lymphadenectomy (ALND) (53% vs 24%, p-value<!--> <!-->=<!--> <!-->0.047). No statistical differences were observed in breast surgery or adjuvant radiotherapy. The percentage of positivity found was 13% (3 micrometastases and 2 macrometastases). 20% of metastases were found in aberrant drainage territories.</div></div><div><h3>Conclusions</h3><div>rSLNB is a feasible and applicable technique in ipsilateral breast tumor recurrence, providing key information in locorregional recurrence management. A considerable percentage of metastases are located in aberrant drainage territories, which would have been missed without rSLNB. Therefore, rSLNB is essential for a correct axillary evaluation in order to trace them.</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"45 2","pages":"Article 500232"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145152572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction of [177Lu]Lu-PSMA-617 treatment response with [68Ga]Ga-PSMA-11 PET-derived variables and correlation of the overall survival with serum PSA and PSMA PET-based response criteria","authors":"E. Ozkan ,&nbsp;B. Demir ,&nbsp;C. Soydal ,&nbsp;M. Araz ,&nbsp;E. Dursun ,&nbsp;N.O. Kucuk ,&nbsp;Y. Urun","doi":"10.1016/j.remnie.2025.500208","DOIUrl":"10.1016/j.remnie.2025.500208","url":null,"abstract":"<div><h3>Purpose</h3><div>In this study we aimed to investigate prediction of response with [68Ga]Ga-PSMA PET-derived parameters and the effectiveness of RECIP criteria and PSA response in predicting survival after [177Lu]Lu-PSMA therapy.</div></div><div><h3>Methods</h3><div>Patients who received at least 2 cycles of [177Lu]Lu-PSMA therapy were retrospectively included in the study. All lesions in the PET images were segmented and PSMA PET-based parameters were extracted. The treatment response was evaluated according to RECIP and PSA criteria. ROC analyses were performed to assess their discriminatory power in predicting response. Correlation of overall survival with RECIP and PSA-based response was evaluated using Kaplan-Meier survival analysis.</div></div><div><h3>Results</h3><div>A total of 41 patients were included in the study. SUVmax, SUVpeak, SUVmean, qPSG-max and qPSG-mean values were significant factors in predicting PSA response. However, in predicting RECIP response (CR + PR), the AUC values for the SUV parameters were not significantly higher than 0.5. In predicting RECIP disease control (CR + PR + SD), the AUC values for SUVmax, SUVpeak, and SUVmean were 0.742(<em>p</em> = 0.002), 0.742(<em>p</em> = 0.002), and 0.722(<em>p</em> = 0.006). In the RECIP-responder and non-responder groups, the median survival was 33.5 and 15.2 months (<em>p</em> = 0.005). In patients with RECIP-disease control and progressive disease, the median survival was 25.1 and 15.2 months (<em>p</em> = 0.002). However, the survival difference between PSA-responder and non-responders groups did not reach significance (<em>p</em> = 0.127).</div></div><div><h3>Conclusion</h3><div>PSMA PET imaging is a useful method to select patients who will most likely to benefit from [177Lu]Lu-PSMA treatment. Also, it has been shown that RECIP has significantly performed better than PSA-based response evaluation in terms of predicting overall survival.</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"45 2","pages":"Article 500208"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145152627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A dynamic nomogram model integrating serum phosphorus and longest diameter enhances diagnostic accuracy of 99mTc-MIBI imaging for parathyroid adenoma patients with elevated parathyroid hormone","authors":"L. Zheng,&nbsp;B. Wang,&nbsp;T. Wu,&nbsp;W. Qu","doi":"10.1016/j.remnie.2025.500228","DOIUrl":"10.1016/j.remnie.2025.500228","url":null,"abstract":"<div><h3>Background</h3><div>Parathyroid adenoma (PA) is the most common cause of primary hyperparathyroidism (PHPT). ^99mTc-methoxyisobutylisonitrile (^99mTc-MIBI) imaging is widely applied in PA diagnosis and location. However, since the individual heterogeneity and adenoma function differences, the diagnostic efficacy of ^99mTc-MIBI imaging is limited, which often leads to misdiagnosis and even mistreatment of PA.</div></div><div><h3>Methods</h3><div>In the present study, we established a novel dynamic nomogram model to assist the nuclear imaging diagnosis of PA. A total of 96 PA patients, with 65 cases in the positive group and 31 cases in the negative group, were enrolled for further analyzing.</div></div><div><h3>Results</h3><div>Univariate analysis showed there were no statistically significant differences between the two groups in terms of gender, age, and adenoma location. The patients in the positive group had significantly higher levels in PTH, serum calcium, longest diameter and shortest diameter of adenoma, compared to those in the negative group. But the serum phosphorus levels were lower in the positive group than in the negative group. Binary logistic regression analysis indicated that serum phosphorus and adenoma longest diameter were independent positive predictors. The dynamic nomogram model was generated by R software and logistic regression analysis (<span><span>https://zhenglong-1988.shinyapps.io/dynnomapp/</span><svg><path></path></svg></span>). The receiver operating characteristics curve (ROC curve) analysis revealed that the cut-off probability for the model to diagnose PA was 59.1%, with AUC values of 0.965.</div></div><div><h3>Conclusions</h3><div>The novel dynamic nomogram diagnostic model integrating serum phosphorus levels and longest diameter could effectively improve the diagnostic accuracy of radionuclide imaging for PA.</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"45 2","pages":"Article 500228"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145067166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive value of metastatic distribution patterns on [68Ga]Ga-PSMA PET/CT for [177Lu]Lu-PSMA therapy","authors":"Y.B. Cayirli ,&nbsp;U. Elboga ,&nbsp;I. Dogan","doi":"10.1016/j.remnie.2025.500205","DOIUrl":"10.1016/j.remnie.2025.500205","url":null,"abstract":"<div><h3>Objective</h3><div>This study aimed to assess the predictive value of metastatic distribution patterns on ⁶⁸Ga-PSMA-11 PET/CT in patients with chemotherapy- and castration-resistant prostate cancer undergoing ¹⁷⁷Lu-PSMA-617 radioligand therapy.</div></div><div><h3>Materials and methods</h3><div>A retrospective analysis was conducted on 48 patients who received ¹⁷⁷Lu-PSMA-617 therapy between April 2019 and August 2023. Demographic, clinical, and laboratory data, along with pre- and post-treatment ⁶⁸Ga-PSMA-11 PET/CT images, were evaluated for associations with molecular response and progression. Whole-body PET/CT segmentation was performed using METAVOL software. Treatment response was classified using RECIP 1.0 criteria, and predictive values were analyzed using SPSS 22.0, with statistical significance set at p &lt; 0.05.</div></div><div><h3>Results</h3><div>Based on RECIP 1.0 criteria, 58.3% (n = 28) responded to therapy, while 41.7% (n = 20) did not. Disease progression was observed in 29.2% (n = 14), and 70.8% (n = 34) showed no progression. Molecular response was significantly associated with parotid SUVmean (OR = 1.137, p = 0.047) and highest miM1 stage (OR = 0.241, p = 0.046). Molecular progression was significantly associated with lymph node metastasis (OR = 0.144, p = 0.006), bone-only metastasis (OR = 4.333, p = 0.030), ln/metTL-PSMA ratio (OR = 0.070, p = 0.042), b/metTL-PSMA ratio (OR = 13.085, p = 0.040), and TL-PSMA-based lymph node dominance over bone metastases (OR = 0.385, p = 0.044).</div></div><div><h3>Conclusion</h3><div>This study highlights the predictive value of metastatic burden distribution on ⁶⁸Ga-PSMA PET/CT in determining treatment outcomes of ¹⁷⁷Lu-PSMA therapy.</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"45 2","pages":"Article 500205"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144995038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[¹⁸F]F-PSMA-PET/CT negative for prostate recurrence but positive for intracranial tumour.","authors":"M D Martínez-Valle Torres, M C Bermúdez Morales, J Venero Chaparro, F J Gari Martínez, D Becerra García","doi":"10.1016/j.remnie.2026.500301","DOIUrl":"10.1016/j.remnie.2026.500301","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":" ","pages":"500301"},"PeriodicalIF":0.0,"publicationDate":"2026-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146777081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}